The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is a chain of interactions between proteins in a cell.
The JAK-STAT signaling pathway transmits information from extracellular chemical signals to the nucleus resulting in DNA transcription and expression of genes involved in immunity, proliferation, differentiation, apoptosis and oncogenesis. This pathway plays a prominent role in mediating signal transduction for many cytokines.
There are three key parts of JAK-STAT signaling pathway: Janus kinases (JAKs), Signal Transducer and Activator of Transcription proteins (STATs), and receptors (which bind the chemical signals). In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors.
Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes.
In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.
Dysregulation of JAK-STAT signaling is associated with various immune disorders. Accumulating evidence has discovered that STAT3 SNPs is associated with Crohn’s disease, psoriasis and ankylosing spondylitis, STAT4 SNPs is associated with rheumatoid arthritis, Crohn’s disease, systemic lupus erythematosus and Sjogren’s syndrome, and STAT6 SNPs is associated with asthma.
Additionally, given the researches implicating JAK-STAT in autoimmune disease and malignancy, it is not surprising that this pathway has become an attractive target for pharmaceuticals. Ruxolitinib, a JAK1 and JAK2 inhibitor with efficacy for the treatment of polycythemia vera and myelofibrosis, was the first FDA approved JAK inhibitor, or Jakinib.
|IL10RA||IL10RA Antibody||IL10RA Protein||IL10RA cDNA||IL10RA ELISA Kit|
|IL10RB||IL10RB Antibody||IL10RB Protein||IL10RB cDNA||IL10RB ELISA Kit|
|IL11||IL11 Antibody||IL11 Protein||IL11 cDNA||IL11 ELISA Kit|
|IL11RA||IL11RA Antibody||IL11RA Protein||IL11RA cDNA||IL11RA ELISA Kit|
|IL12A||IL12A Antibody||IL12A Protein||IL12A cDNA||IL12A ELISA Kit|
|IL12B||IL12B Antibody||IL12B Protein||IL12B cDNA||IL12B ELISA Kit|
|IL12RB1||IL12RB1 Antibody||IL12RB1 Protein||IL12RB1 cDNA||IL12RB1 ELISA Kit|
|IL12RB2||IL12RB2 Antibody||IL12RB2 Protein||IL12RB2 cDNA||IL12RB2 ELISA Kit|
|IL13||IL13 Antibody||IL13 Protein||IL13 cDNA||IL13 ELISA Kit|
|IL13RA1||IL13RA1 Antibody||IL13RA1 Protein||IL13RA1 cDNA||IL13RA1 ELISA Kit|
|IL13RA2||IL13RA2 Antibody||IL13RA2 Protein||IL13RA2 cDNA||IL13RA2 ELISA Kit|
|IL15||IL15 Antibody||IL15 Protein||IL15 cDNA||IL15 ELISA Kit|
|IL15RA||IL15RA Antibody||IL15RA Protein||IL15RA cDNA||IL15RA ELISA Kit|
|IL17D||IL17D Antibody||IL17D Protein||IL17D cDNA||IL17D ELISA Kit|
|IL19||IL19 Antibody||IL19 Protein||IL19 cDNA||IL19 ELISA Kit|
|IL2||IL2 Antibody||IL2 Protein||IL2 cDNA||IL2 ELISA Kit|
|IL20||IL20 Antibody||IL20 Protein||IL20 cDNA||IL20 ELISA Kit|
|IL20RA||IL20RA Antibody||IL20RA Protein||IL20RA cDNA||IL20RA ELISA Kit|
|IL20RB||IL20RB Antibody||IL20RB Protein||IL20RB cDNA||IL20RB ELISA Kit|
|IL21||IL21 Antibody||IL21 Protein||IL21 cDNA||IL21 ELISA Kit|